Safety issues with intravenous iron products in the management of anemia in chronic kidney disease
about
Iron deficiency anemiaIron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?Anemia in critical illness: insights into etiology, consequences, and managementCost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative periodThe impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.Is there any role of intravenous iron for the treatment of anemia in cancer?Iron Therapy Challenges for the Treatment of Nondialysis CKD PatientsA Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.Iron deficiency anaemia in chronic kidney disease.Iron deficiency anemia in the emergency department: over-utilization of red blood cell transfusion and infrequent use of iron supplementation.Percentage of hypochromic erythrocytes and reticulocyte hemoglobin equivalent predictors of response to intravenous iron in hemodialysis patients.Whole-body iron transport and metabolism: Mechanistic, multi-scale model to improve treatment of anemia in chronic kidney disease.Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study
P2860
Q27021693-54B0DE2A-0071-4F7D-8C08-6600BA4B1FE0Q28088503-C2A0143A-D123-4B76-9A27-0BC24BB034EAQ33738712-133A09C0-3765-4487-9AE9-B61FF0C35EF9Q34429565-354ACC11-0E93-49E0-8550-748B07D1ABE2Q34492729-B6E92ED3-F1B5-47A4-87DD-1793DD69A117Q35549440-31F731D9-A74E-4DEC-9D6A-0DC68D92FF7CQ36108113-172F74ED-7B6E-4834-B9CD-AFB942C9D852Q37069943-C87BB1A7-B496-477E-9712-4298A293C106Q37838114-978AB93E-4C15-462A-B3B3-FBC0A45AEA63Q37874704-0D3C7C98-0C9E-4905-BC95-B63D3D669C8FQ38126230-92A8B10C-5D62-44D1-B71F-3864DEEF777CQ39000612-DD916149-7C2D-49BE-8B27-40EFA7C06ED5Q50240951-99D96FDA-2C7B-4B71-AED5-7E14A3AC7F4AQ52586092-72D9CF9C-8F44-4CCA-96FF-48E6570FDA1FQ57213827-AC850CEF-0E8A-4959-8FB5-8E535695C32B
P2860
Safety issues with intravenous iron products in the management of anemia in chronic kidney disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety issues with intravenous ...... emia in chronic kidney disease
@en
Safety issues with intravenous ...... mia in chronic kidney disease.
@nl
type
label
Safety issues with intravenous ...... emia in chronic kidney disease
@en
Safety issues with intravenous ...... mia in chronic kidney disease.
@nl
prefLabel
Safety issues with intravenous ...... emia in chronic kidney disease
@en
Safety issues with intravenous ...... mia in chronic kidney disease.
@nl
P2860
P356
P1476
Safety issues with intravenous ...... emia in chronic kidney disease
@en
P2093
Amir Hayat
P2860
P304
P356
10.3121/CMR.2008.811
P577
2008-12-01T00:00:00Z